Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deadline Approaching: Apply for the Fierce AI Innovation Awards
antibody-drug conjugates
Pharma
Gilead's Trodelvy stumbles in first-line NSCLC
Despite Trodelvy's flop, analysts remain hopeful that Merck's rival TROP2 ADC, sac-TMT, can succeed in the same first-line NSCLC setting.
Angus Liu
Jun 9, 2026 11:14am
Patient deaths raise questions about ADC's cancer drug Zynlonta
Jun 4, 2026 11:38am
At ASCO, China biotech industry cements its coming of age
Jun 3, 2026 8:50am
Will Merck close a gap in sac-TMT's massive ph. 3 program?
Jun 1, 2026 4:30am
AbbVie scores FDA green light for another ImmunoGen asset
May 28, 2026 7:27am
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
May 27, 2026 11:25am
